A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Cytarabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors AbbVie
- 09 Nov 2017 Planned End Date changed from 4 Apr 2020 to 25 Nov 2019.
- 29 Sep 2017 Planned End Date changed from 20 Oct 2019 to 4 Apr 2020.
- 31 Jul 2017 Planned End Date changed from 2 Dec 2019 to 20 Oct 2019.